Global /United States /Healthcare /Biotechnology /ENZC

Enzolytics, Inc.

ENZC

• OTCMKTS: ENZC • Delayed

0.0003USD 0%

As of 13 June 2026, Enzolytics, Inc. has a market cap of $1.45M USD, ranking #47859 globally and #6119 in the United States. It ranks #4242 in the Healthcare sector, and #826 in the Biotechnology industry.

Global Rank

47859

Country Rank

6119

Sector Rank

4242

Industry Rank

826

Key Stats

Market Cap

$1.45MUSD

Revenue (TTM)

$46.59KUSD

EBITDA (TTM)

-$886.77KUSD

Net Income (TTM)

-$1.03MUSD

PS Ratio

31.1

PB Ratio

-2.0

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Steven Sharabura open_in_new

Website

enzolytics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-25%	0%	-50%	-25%	0%	-57%	-100%	-100%

News

Markets

Exchange	Ticker	Price	Quotes
OTC Markets (OTCMKTS / OTC) MIC: OTCM PRIMARY	ENZC Enzolytics Inc ISIN: US2941121079 Shares Out.: Shares Outstanding: 4.831B¹ Shares Float: 4.737B² TV: TradingView: OTC: ENZC SA: Stock Analysis: OTC: ENZC YF: Yahoo Finance: ENZC GF: Google Finance: OTCMKTS: ENZC BA: Barron's: ENZC MS: Morningstar: PINX: ENZC	0.0003 USD	TV: TradingView: OTC: ENZC SA: Stock Analysis: OTC: ENZC YF: Yahoo Finance: ENZC GF: Google Finance: OTCMKTS: ENZC BA: Barron's: ENZC MS: Morningstar: PINX: ENZC

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Enzolytics, Inc.

Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company’s proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 13M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 11M%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 2M%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 2M%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 2M%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 1M%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 3M%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 3M%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 3M%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 3M%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 2M%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 2M%	-	Germany

chevron_leftBack